We are live on
!
Find out more
ARS Pharmaceuticals
SPRY
SPRY
189 hedge funds and large institutions have $1.04B invested in ARS Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more capital invested
Capital invested by funds: $840M → $1.04B (+$196M)
13% more call options, than puts
Call options by funds: $4.56M | Put options by funds: $4.04M
5.38% more ownership
Funds ownership: 84.63% → 90.01% (+5.4%)
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
1% more funds holding
Funds holding: 188 → 189 (+1)
Holders
189
Holders Change
+1
Holders Change %
+0.53%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
37
Increased
58
Reduced
55
Closed
34
Calls
$4.56M
Puts
$4.04M
Net Calls
+$519K
Net Calls Change
-$5.5M
Top Buyers
| 1 |
Millennium Management
New York
|
+$30.8M |
| 2 |
TCM
Tyro Capital Management
Miami,
Florida
|
+$19.4M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$16.5M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.1M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$7.88M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$25.1M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$13.1M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$10.4M |
| 4 |
EP
Eversept Partners
New York
|
-$7.05M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$5.95M |
